BRAD LONCAR

BIOTECH DATA

HOME

Rubraca sales over time

This page will track the quarterly sales of Clovis Oncology's PARP inhibitor Rubraca over time.

Rubraca Sales

< Back Home

Who Am I?
Brad Loncar

I'm an individual investor from Kansas City.  My focus is on biotech stocks, but I enjoy investing in all industries. I'm an old-school, buy and hold investor who believes the best way to outperform and grow capital is to own innovative companies with good management teams over the long-term. more>>>

More on the web

A recent CNBC appearance

My Xconomy opinion pieces

An interview with WCG

Follow Me
  • Twitter App Icon
  • Stocktwits.jpg
  • YouTube Classic
  • Google+ Classic
Resources

Keytruda vs Opdivo Sales

Entresto Sales

Praluent vs Repatha Sales

Eylea Sales

Illumina Quarterly Revenue

GILD HCV Sales

Yervoy Sales

Jakafi Sales

Imbruvica Sales - J&J

Tecfidera Sales

Kadcyla Sales

Gazyva Sales

Cologuard Tests Completed

ADCETRIS Sales

BLINCYTO Sales

HETLIOZ Sales

Vertex CF Sales

Strensiq Sales

Imbruvica Sales - ABBV

VIVITROL Sales

Ibrance Sales

Auryxia Sales

Linzess Sales

RAVICTI Sales

Makena Sales

Halozyme Royalty Revenue

Myriad Hereditary Cancer

Zytiga Sales

Intuitive Surgical Revenue

Tecentriq Sales

Darzalex Sales

Exondys 51 Sales

Spinraza Sales

NUPLAZID Sales

Horizon Primary Care

Lynparza Sales

Imfinzi Sales

Rubraca Sales

Zejula Sales

Vascepa Sales

Cabozantinib Franchise

Dupixent

Yescarta Sales

Kymriah Sales

NERLYNX Sales

Ocaliva Sales

Translarna Sales

Omidria Sales